Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 17 March 2000:
Vol. 287. no. 5460, pp. 1969 - 1973
DOI: 10.1126/science.287.5460.1969
Prev | Table of Contents | Next

Review

Mechanism-Based Target Identification and Drug Discovery in Cancer Research

Jackson B. Gibbs

Cancer as a disease in the human population is becoming a larger health problem, and the medicines used as treatments have clear limitations. In the past 20 years, there has been a tremendous increase in our knowledge of the molecular mechanisms and pathophysiology of human cancer. Many of these mechanisms have been exploited as new targets for drug development in the hope that they will have greater antitumor activity with less toxicity to the patient than is seen with currently used medicines. The fruition of these efforts in the clinic is just now being realized with a few encouraging results.

Department of Cancer Research, Merck Research Laboratories, West Point, PA 19486, USA. E-mail: jay_gibbs{at}merck.com

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo.
M Celano, S Schenone, D Cosco, M Navarra, E Puxeddu, L Racanicchi, C Brullo, E Varano, S Alcaro, E Ferretti, et al. (2008)
Endocr. Relat. Cancer 15, 499-510
   Abstract »    Full Text »    PDF »
Multiparametric Cell Cycle Analysis by Automated Microscopy.
F. Gasparri, P. Cappella, and A. Galvani (2006)
J Biomol Screen 11, 586-598
   Abstract »    PDF »
TarFisDock: a web server for identifying drug targets with docking approach..
H. Li, Z. Gao, L. Kang, H. Zhang, K. Yang, K. Yu, X. Luo, W. Zhu, K. Chen, J. Shen, et al. (2006)
Nucleic Acids Res. 34, W219-W224
   Abstract »    Full Text »    PDF »
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies..
P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit (2006)
J Natl Cancer Inst 98, 580-598
   Abstract »    Full Text »    PDF »
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers..
M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. (2006)
Mol. Cancer Ther. 5, 767-775
   Abstract »    Full Text »    PDF »
YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] Exhibits a Novel Antiproliferative Effect and Arrests the Cell Cycle in G0-G1 in Human Hepatocellular Carcinoma Cells.
S.-W. Wang, S.-L. Pan, J.-H. Guh, H.-L. Chen, D.-M. Huang, Y.-L. Chang, S.-C. Kuo, F.-Y. Lee, and C.-M. Teng (2005)
J. Pharmacol. Exp. Ther. 312, 917-925
   Abstract »    Full Text »    PDF »
Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells.
D. J. Marciniak, A. K. Rishi, F. H. Sarkar, and A. P.N. Majumdar (2004)
Mol. Cancer Ther. 3, 1615-1621
   Abstract »    Full Text »    PDF »
In Vivo Measurement of Microtubule Dynamics Using Stable Isotope Labeling with Heavy Water: EFFECT OF TAXANES.
P. Fanara, S. Turner, R. Busch, S. Killion, M. Awada, H. Turner, A. Mahsut, K. L. LaPrade, J. M. Stark, and M. K. Hellerstein (2004)
J. Biol. Chem. 279, 49940-49947
   Abstract »    Full Text »    PDF »
Expression of N-Acetylglucosaminyltransferase V Is Associated with Prognosis and Histology in Non-Small Cell Lung Cancers.
H. Dosaka-Akita, E. Miyoshi, O. Suzuki, T. Itoh, H. Katoh, and N. Taniguchi (2004)
Clin. Cancer Res. 10, 1773-1779
   Abstract »    Full Text »    PDF »
Induction of Apoptosis and Down-Regulation of Bcl-XL in Cancer Cells by a Novel Small Molecule, 2[ [3-(2,3-Dichlorophenoxy)propyl]amino]ethanol.
S. Wu, H. Zhu, J. Gu, L. Zhang, F. Teraishi, J. J. Davis, D. A. Jacob, and B. Fang (2004)
Cancer Res. 64, 1110-1113
   Abstract »    Full Text »    PDF »
Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound.
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos (2003)
Clin. Cancer Res. 9, 5776-5785
   Abstract »    Full Text »    PDF »
Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10.
G. Stassi, M. Todaro, M. Zerilli, L. Ricci-Vitiani, D. Di Liberto, M. Patti, A. Florena, F. Di Gaudio, G. Di Gesu, and R. De Maria (2003)
Cancer Res. 63, 6784-6790
   Abstract »    Full Text »    PDF »
Systematic discovery of multicomponent therapeutics.
A. A. Borisy, P. J. Elliott, N. W. Hurst, M. S. Lee, J. Lehar, E. R. Price, G. Serbedzija, G. R. Zimmermann, M. A. Foley, B. R. Stockwell, et al. (2003)
PNAS 100, 7977-7982
   Abstract »    Full Text »    PDF »
Oncology Drug Discovery Applications Using the FmatTM 8100 Hts System.
J. Y. Lee, S. Miraglia, X. Yan, E. Swartzman, S. Cornell-Kennon, J. Mellentin-Michelotti, C. Bruseo, and D. S. France (2003)
J Biomol Screen 8, 81-88
   Abstract »    PDF »
Csk Homologous Kinase (CHK) and ErbB-2 Interactions Are Directly Coupled with CHK Negative Growth Regulatory Function in Breast Cancer.
S. Kim, R. Zagozdzon, A. Meisler, J. D. Baleja, Y. Fu, S. Avraham, and H. Avraham (2002)
J. Biol. Chem. 277, 36465-36470
   Abstract »    Full Text »    PDF »
Cancer Prevention Science and Practice.
S. M. Lippman and W. K. Hong (2002)
Cancer Res. 62, 5119-5125
   Full Text »    PDF »
Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention.
R. Buettner, L. B. Mora, and R. Jove (2002)
Clin. Cancer Res. 8, 945-954
   Abstract »    Full Text »    PDF »
Systems Biology: A Brief Overview.
H. Kitano (2002)
Science 295, 1662-1664
   Abstract »    Full Text »    PDF »
Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues.
M. J. Thun, S. J. Henley, and C. Patrono (2002)
J Natl Cancer Inst 94, 252-266
   Abstract »    Full Text »    PDF »
Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening.
F. M. Balis (2002)
J Natl Cancer Inst 94, 78-79
   Full Text »    PDF »
TTD: Therapeutic Target Database.
X. Chen, Z. L. Ji, and Y. Z. Chen (2002)
Nucleic Acids Res. 30, 412-415
   Abstract »    Full Text »    PDF »
Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma.
Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik (2002)
J. Immunol. 168, 466-474
   Abstract »    Full Text »    PDF »
A Risk-Stratification Model of Non-Small Cell Lung Cancers Using Cyclin E, Ki-67, and ras p21: Different Roles of G1 Cyclins in Cell Proliferation and Prognosis.
H. Dosaka-Akita, F. Hommura, T. Mishina, S. Ogura, M. Shimizu, H. Katoh, and Y. Kawakami (2001)
Cancer Res. 61, 2500-2504
   Abstract »    Full Text »
Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview.
P. E. Blackshear (2001)
Toxicol Pathol 29, 105-116
   Abstract »    PDF »
Nucleic acid-triggered catalytic drug release.
Z. Ma and J.-S. Taylor (2000)
PNAS 97, 11159-11163
   Abstract »    Full Text »    PDF »
Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Suppresses TKR-Growth Factor Signaling Independent of Metalloproteinase Inhibition.
S. E. Hoegy, H.-R. Oh, M. L. Corcoran, and W. G. Stetler-Stevenson (2001)
J. Biol. Chem. 276, 3203-3214
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)